-
New Phase 2 Trial Launches for VS-7375 in KRAS G12D-Mutated Colorectal Cancer
A new Phase 2 clinical trial is underway to evaluate VS-7375, a targeted therapy being studied alone and in combination with established treatments for patients with a specific type of metastatic colorectal cancer.
-
New Clinical Trial Launches to Evaluate COYA 302 for ALS Treatment
The ALSTARS trial will test COYA 302, a dual-mechanism immunomodulatory therapy, across 20-25 sites in the US and Canada to assess its potential to help slow ALS progression.
-
TearSolutions’ NK Peptide Therapy Earns Two Special FDA Designations
TearSolutions has received two significant FDA designations for its NK peptide therapy, a milestone that could accelerate the path toward new treatment options for patients with tear-deficient eye conditions.
-
FDA Signals Move to Ease Restrictions on Certain Peptides
The FDA is reportedly moving toward loosening restrictions on certain peptide compounds, a shift that could expand access and support further development in the peptide space.
-
Oral GLP-1 Contender: CU Anschutz Explores Orforglipron for Weight Loss
Researchers at the University of Colorado Anschutz Medical Campus are studying orforglipron, an investigational oral GLP-1 medication that could offer a needle-free alternative for weight management.
-
FDA Advisory Panel Backs Continued Access to Compounded Peptides
An FDA advisory panel has voted to allow certain unapproved peptides to remain available through compounding pharmacies, preserving a pathway for patients and providers who rely on these customized preparations.
-
FDA Advisory Panel Backs Easing Restrictions on Six Popular Peptides
An FDA advisory committee has voiced support for loosening restrictions on six peptides, a move that could expand access for patients and practitioners. The decision now heads toward further regulatory review.
-
Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story
Tesamorelin’s FDA approval highlights how growth hormone-releasing hormone (GHRH) analogs have moved from research interest into legitimate, regulated clinical use. Its journey offers an encouraging case study for the broader peptide field.
-
US Health Panel Eases Restrictions on Popular Peptides, Expanding Access
A U.S. health advisory panel has voted to loosen restrictions on several peptides that have grown popular online, potentially opening the door to wider availability through compounding pharmacies.
-
Lilly Advances Toward FDA Approval for Retatrutide, a Promising Triple-Action Obesity Peptide
Eli Lilly plans to submit new clinical data to the FDA for retatrutide, an investigational triple-hormone-receptor peptide showing strong results in obesity research.